BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Ceregene, Inc. 

9381 Judicial Drive
Suite 130
San Diego  California  92121  U.S.A.
Phone: 858-458-8800 Fax: 858-458-8801


SEARCH JOBS


Industry
Biotechnology






 Company News
Sangamo BioSciences, Inc. (SGMO) to Acquire Ceregene, Inc. 8/27/2013 6:45:41 AM    More...
Ceregene, Inc. Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5/21/2013 10:17:28 AM    More...
Ceregene, Inc. Reports Data From Parkinson's Disease Phase 2b Study 4/22/2013 9:56:37 AM    More...
Ceregene, Inc. and Alzheimer's Disease Cooperative Study Group Complete Enrollment of CERE-110 Phase 2 Trial 3/13/2013 9:49:03 AM    More...
Ceregene, Inc. Parkinson's Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin) 5/17/2012 1:01:13 PM    More...
Ceregene, Inc. Completes Enrollment of Second Phase 2 Study of CERE-120 for the Treatment of Parkinson's Disease 12/1/2011 12:29:34 PM    More...
Ceregene, Inc. Reports New Findings Regarding How Parkinson's Brains Respond to Neurotrophic Factors 2/15/2011 7:22:25 AM    More...
Ceregene, Inc. Advances Phase 2b CERE-120 (AAV2-neurturin) Trial in Parkinson's Disease 2/3/2011 7:12:49 AM    More...
Ceregene, Inc. Raises $11.5 Million in Series D Financing 11/11/2010 6:20:30 AM    More...
Ceregene, Inc. Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinson's Disease 10/20/2010 7:40:43 AM    More...
1234

//-->